CN104127533B - 复方支气管炎糖浆及制备方法 - Google Patents
复方支气管炎糖浆及制备方法 Download PDFInfo
- Publication number
- CN104127533B CN104127533B CN201410399119.0A CN201410399119A CN104127533B CN 104127533 B CN104127533 B CN 104127533B CN 201410399119 A CN201410399119 A CN 201410399119A CN 104127533 B CN104127533 B CN 104127533B
- Authority
- CN
- China
- Prior art keywords
- preparation
- saccharide
- syrup
- radix
- bronchitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 33
- 239000006188 syrup Substances 0.000 title claims abstract description 33
- 235000020357 syrup Nutrition 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 21
- 229940098391 carbetapentane citrate Drugs 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 21
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 20
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 20
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 19
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 19
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 9
- 230000008020 evaporation Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000005325 percolation Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 235000021551 crystal sugar Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract description 2
- 230000009325 pulmonary function Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 210000003437 trachea Anatomy 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 description 26
- 206010062717 Increased upper airway secretion Diseases 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 208000026435 phlegm Diseases 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 10
- 206010036790 Productive cough Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010025482 malaise Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010038727 Respiratory tract haemorrhage Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008020 pharmaceutical preservative Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410399119.0A CN104127533B (zh) | 2014-08-14 | 2014-08-14 | 复方支气管炎糖浆及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410399119.0A CN104127533B (zh) | 2014-08-14 | 2014-08-14 | 复方支气管炎糖浆及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104127533A CN104127533A (zh) | 2014-11-05 |
CN104127533B true CN104127533B (zh) | 2016-03-30 |
Family
ID=51800555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410399119.0A Active CN104127533B (zh) | 2014-08-14 | 2014-08-14 | 复方支气管炎糖浆及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104127533B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104434789B (zh) * | 2014-12-27 | 2017-04-26 | 昆明振华制药厂有限公司 | 一种枸橼酸喷托维林糖浆的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060212A (zh) * | 1991-07-20 | 1992-04-15 | 肖水源 | 儿童、老年人支气管炎散的配方及制作方法 |
CN1650889A (zh) * | 2004-11-29 | 2005-08-10 | 俞锋 | 一种小儿止咳糖浆及其制备方法 |
CN103550705A (zh) * | 2013-10-31 | 2014-02-05 | 青岛绿曼生物工程有限公司 | 治疗犬传染性支气管炎的组合物及其制备方法 |
-
2014
- 2014-08-14 CN CN201410399119.0A patent/CN104127533B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060212A (zh) * | 1991-07-20 | 1992-04-15 | 肖水源 | 儿童、老年人支气管炎散的配方及制作方法 |
CN1650889A (zh) * | 2004-11-29 | 2005-08-10 | 俞锋 | 一种小儿止咳糖浆及其制备方法 |
CN103550705A (zh) * | 2013-10-31 | 2014-02-05 | 青岛绿曼生物工程有限公司 | 治疗犬传染性支气管炎的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104127533A (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103920106A (zh) | 一种治疗慢性支气管炎和支气管哮喘的中药组合物 | |
CN103536889B (zh) | 一种治疗老年慢性气管炎合并肺气肿的中药汤剂 | |
CN104042713B (zh) | 一种治疗支气管哮喘病的中药组合物 | |
CN104127533B (zh) | 复方支气管炎糖浆及制备方法 | |
CN104001131A (zh) | 一种防治应激性溃疡的内服中药 | |
CN106728010A (zh) | 一种用于畜禽咳喘的药物组合物及其制备工艺 | |
CN103495130B (zh) | 一种用于治疗气喘的中药组合物 | |
CN106334114A (zh) | 一种治疗咽炎的中药及其制备方法 | |
CN102106999A (zh) | 一种治疗中风病后吞咽困难的中药复方制剂及其制备方法 | |
CN104623152A (zh) | 一种治疗痰湿凝聚型甲状腺腺瘤的中药组合物及制备方法 | |
CN103830481A (zh) | 治疗小儿反复呼吸道感染的药物 | |
CN103638323A (zh) | 治疗慢性萎缩性胃炎的中药丸剂 | |
CN106620266A (zh) | 一种治疗猪气喘病的中药组合物 | |
CN102784307A (zh) | 一种用于治疗肺结核的中药及制备方法 | |
CN106334155A (zh) | 一种治疗动甲状腺肿大的中药组合物及其制备方法 | |
CN105168847A (zh) | 一种用于治疗幽门螺杆菌感染性消化性溃疡的中药 | |
CN104127481A (zh) | 小儿支气管炎咳宁糖浆及制法 | |
CN104887949B (zh) | 一种治疗扩张性心肌病的中药制剂及其制备方法 | |
CN105168860A (zh) | 一种治疗小儿哮喘的中药组合物及其制备方法 | |
CN104840864A (zh) | 一种治疗小儿脾虚型腹泻的中药制剂 | |
CN104258361A (zh) | 一种治疗小儿哮喘的中药组合物 | |
CN104784567B (zh) | 一种治疗泌尿系感染的药物组合物 | |
CN104127504B (zh) | 小儿感冒咳嗽糖浆及其制备方法 | |
CN103550666B (zh) | 一种治疗慢性支气管炎的药物 | |
CN102091154A (zh) | 治疗气管炎的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Yinghui Inventor after: Fu Qiang Inventor before: Sun Fafeng |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160219 Address after: 266000 Shandong Province, Qingdao city Jiaxiang Road No. 3 Applicant after: Liu Yinghui Address before: 250101 agile garden area, hi tech Zone, Ji'nan, Shandong Applicant before: Sun Fafeng |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221221 Address after: No. 166, Chemical Road, Boxing Economic Development Zone, Boxing County, Binzhou City, Shandong Province, 256500 Patentee after: Boxing Xingye intelligent new material Co.,Ltd. Address before: No.3, Jiaxiang Road, Shinan District, Qingdao City, Shandong Province 266000 Patentee before: Liu Yinghui |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240320 Address after: 730314 No. 2299 middle section of Kunlun Mountains Avenue, Lanzhou New District, Lanzhou, Gansu. Patentee after: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Country or region after: Zhong Guo Address before: No. 166, Chemical Road, Boxing Economic Development Zone, Boxing County, Binzhou City, Shandong Province, 256500 Patentee before: Boxing Xingye intelligent new material Co.,Ltd. Country or region before: Zhong Guo |
|
TR01 | Transfer of patent right |